These results demonstrate that celastrol and erastin cotreatment exerts anticancer effects on NSCLC xenografts and that the inhibition of HSF1 further potentiated this synergistic therapeutic effect. The gene discussed is HSF1; the disease is non-small cell lung carcinoma.